Last reviewed · How we verify

NCT06798077: CAM Cohort

Chronic Airway Disease and Multimorbidity Cohort

Recruiting now Last updated 17 February 2025
What this trial tests

trial in Chronic Obstructive Pulmonary Disease (COPD) in 2,000 participants. Currently enrolling.

Timeline
1 February 2025
Primary endpoint
31 July 2028
31 July 2028

Quick facts

Lead sponsorChina-Japan Friendship Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,000
Start date1 February 2025
Primary completion31 July 2028
Estimated completion31 July 2028
Sites9 locations across China

Conditions studied

Sponsor

China-Japan Friendship Hospital

Who can join

18 and older, any sex, with Chronic Obstructive Pulmonary Disease (COPD) or Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis, are highly prevalent and cause serious disease burden. Multimorbidity is recognized to influence treatment decision and prognosis of patients with stable CAD. The impact of multimorbidity on exacerbation CAD is under investigated. Methods: The Chronic Airway Disease and Multimorbidity (CAM) cohort study is a prospective, multicenter, observational study aiming to recruit a minimum of 2000 patients hospitalized for exacerbation of COPD, asthma or bronchiectasis. Comprehensive data, including demographics, medical history, comorbidities, lung function, echocardiography, microbiological profiles, radiology, quality of life and treatment will be collected at baseline during the hospitalization. Follow-up data indicating the impact of both CAD and multimorbidity will be collected at 1-, 3-, 6-, 9- and 12-months after hospital discharge. Biospecimens, including blood and bronchoalveolar lavage fluid, will be collected and analyzed for biomarker detecting. Primary outcome are length of hospital stay and re-exacerbation during fellow-up. Secondary outcomes include comorbidity pattern and its impact on respiratory symptoms burden, quality of life, pulmonary function and chest imaging as well as cost and healthcare utilization. Conclusions: The knowledge generated from CAM cohort study will fill crucial gaps in understanding how multimorbidity affects CAD and facilitate evidence-based clinical practice in the future.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease (COPD)

Currently open trials in the same condition.

Other China-Japan Friendship Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06798077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing